ADC Therapeutics SA Operating Income Loss

• ADC Therapeutics SA showed an increase of +7.0% in Operating Income Loss from 2024 to 2025.
• This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 4 years of available data (2022 to 2025), ADC Therapeutics SA's Operating Income Loss has grown by 1.5%.
• Historical annual values: Fiscal year 2025: -$121.50 million | Fiscal year 2024: -$130.65 million | Fiscal year 2023: -$165.99 million | Fiscal year 2022: -$123.34 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026